There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mediwound (MDWD) and Petiq Inc (PETQ) with bullish sentiments.
Mediwound (MDWD)
Oppenheimer analyst Jay Olson maintained a Buy rating on Mediwound today and set a price target of $15. The company’s shares opened today at $5.35.
Olson said:
“MDWD signed a deal with VCEL to commercialize $17.5M upfront, another $7.5M contingent upon US approval and up to $125M contingent on annual sales milestones. MDWD will also receive tiered royalties on net sales (excluding BARDA) ranging from high single digits to low double digits. For BARDA sales, MDWD will receive a split of gross profits on committed procurement orders and double-digit royalties on any future BARDA purchases of NexoBrid. MDWD will manufacture NexoBrid and sell it at cost plus fixed margin to VCEL. While MDWD retains ex-US rights to NexoBrid, this deal clearly shifts focus to EscharEx which we view as the larger of the two opportunities. We maintain our Outperform rating with details inside.”
According to TipRanks.com, Olson is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.5% and a 40.8% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Enanta Pharmaceuticals.
Currently, the analyst consensus on Mediwound is a Strong Buy with an average price target of $11.
See today’s analyst top recommended stocks >>
Petiq Inc (PETQ)
Oppenheimer analyst Brian Nagel maintained a Buy rating on Petiq Inc today. The company’s shares opened today at $27.70.
According to TipRanks.com, Nagel is a 5-star analyst with an average return of 9.4% and a 66.9% success rate. Nagel covers the Services sector, focusing on stocks such as Weight Watchers International, Dick’s Sporting Goods, and Advance Auto Parts.
Petiq Inc has an analyst consensus of Strong Buy, with a price target consensus of $41.50, which is a 49.8% upside from current levels. In a report issued on April 30, SunTrust Robinson also reiterated a Buy rating on the stock with a $40 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
